This view is supported by Zeppernick (2015), who wrote that the BRAF mutation shows upregulation of glucose transporter-1 (GLUT1), which is an essential surface protein that leads to the increase in glucose metabolism required to overcome OIS-associated senescence and tumor progression [8]. The gene discussed is SLC2A1; the disease is neoplasm.